AstraZeneca Aktie 982352 / GB0009895292
131.62
CHF
2.16
CHF
1.66%
18:00:00
BRX
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | Ausblick | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 94.93 |
| Government Pension Fund - Global (The) | 2.32 |
| Vanguard Total International Stock Index Fund | 1.26 |
| Vanguard Health Care Fund | 1.25 |
| American Funds EuroPacific Growth Fund | 0.88 |
| Goldman Sachs GQG Partners International Opportunities Fund | 0.78 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 64'400 | 70'600 | 76'100 | 83'100 | 83'500 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.26 | 0.27 | 0.28 | 0.33 | 0.43 |
Bilanz (in Mio. EUR) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 12'184 | 11'748 | 14'298 | 19'376 | 18'782 |
| Summe Anlagevermögen | 24'797 | 23'668 | 26'337 | 51'718 | 55'091 |
| Summe Aktiva | 47'622 | 46'331 | 48'816 | 77'790 | 80'209 |
Bilanz (in Mio. EUR) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 15'007 | 13'759 | 14'909 | 22'726 | 24'301 |
| Summe Fremdkapital | 36'595 | 35'313 | 37'376 | 48'784 | 49'401 |
| Summe Eigenkapital | 11'027 | 11'018 | 11'440 | 29'006 | 30'807 |
| Summe Passiva | 47'622 | 46'331 | 48'816 | 77'790 | 80'209 |
Adresse
| Cambridge Biomedical Campus, CB2 0AA Cambridge | |
| Telefon | +44 (20) 3749-5000 |
| URL | http://www.astrazeneca.com |
Management
|
Adrian Charles Noel Kemp
Secretary |
|
Ahmed M. Hamdy
Member |
|
Alberto Hegewisch
Chief Medical Officer |
|
Andreas Rummelt
Non-Executive Director |
|
Aradhana Sarin
Chief Financial Officer & Executive Director |
|
Cindy L. Hoots
Chief Digital & Information Officer |
|
David Fredrickson
Executive Vice President-Oncology Business Unit |
|
Deborah DiSanzo
Independent Non-Executive Director |
|
Diana Layfield
Non-Executive Director |
|
Euan A. Ashley
Non-Executive Director |
|
Helen MacPhee
Vice President |
|
Iskra Reic
Executive Vice President-Europe & Canada |
|
Jeffrey Pott
CHRO, Chief Compliance Officer & General Counsel |
|
Jonathan Thomas Charles Slade
Group Treasurer |
|
Katarina Ageborg
Chief Compliance Officer & EVP-Sustainability |
|
Kevin G. Lokay
Head-Change Implementation |
|
Marc Pierre Jean Dunoyer
Chief Strategy Officer |
|
Marcus Wallenberg
Independent Non-Executive Director |
|
Margareta Elisabeth Björk
Senior VP & Head-Late-stage Development |
|
Mark White
Global Franchise Head-Fasenra |
|
Menelas NICOLAS Pangalos
EVP-Biopharmaceuticals Research & Development |
|
Michel Demaré
Chairman |
|
Nazneen Rahman
Independent Non-Executive Director |
|
Pam P. Cheng
Executive VP-Operations & Information Technology |
|
Pascal Soriot
Chief Executive Officer & Executive Director |
|
Philip Arthur John Broadley
Senior Independent Non-Executive Director |
|
Regina Fritsche Danielson
SVP, Head-Research & Early Development |
|
Ruud Dobber
Executive VP-Biopharmaceuticals Business |
|
Sarah Miksinski
Senior Director-Global Regulatory Affairs |
|
Sherilyn D. McCoy
Independent Non-Executive Director |
|
Sjoerd Hubben
Vice President-Global Government Affairs & Policy |
|
Susan Mary Galbraith
Executive VP-Oncology Research & Development |
|
Tony Mok
Independent Non-Executive Director |
|
Tyrell J. Rivers
Executive Director-Corporate Development |